Qual Life Res ;5: Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: Measurement of health status: Patients classified as having improved by the anchor tended to have better HRQoL scores, and those classified as deteriorated by the anchor tended to have worse HRQoL scores, while those classified as not changed by the anchor generally did not appear to have changed in their HRQoL i. JewittWarren P. In light of this, we restricted analysis of physical and role functioning domains only to the most recent version of the questionnaire; the one that uses the 4-point scale. A combination of distribution- and anchor-based approaches determined minimally important differences MIDs for four endpoints in a breast cancer scale. Based on these two studies, mean differences of 10 points or more are widely viewed as being clinically significant when interpreting the results of randomized clinical trials that use the QLQ-C30 [ 15 ].
|Published (Last):||13 January 2005|
|PDF File Size:||1.28 Mb|
|ePub File Size:||4.62 Mb|
|Price:||Free* [*Free Regsitration Required]|
The aim of this module was to evaluate the effects of the tumour and its treatment on symptoms, functions and health-related quality of life HRQoL of brain tumour patients, both in clinical trials and clinical practice. Since the publication of the QLQ-BN20 in , we have observed an increase in the use of this questionnaire, not only in glioma patients whom this questionnaire was developed in and validated for, but also in patients with other types of brain tumours, such as meningioma patients and patients with brain metastases from systemic cancer.
Despite the fact that use of the QLQ-BN20 has tremendously contributed to insight into the quality of life of brain tumour patients, certain items of the questionnaire have raised issues e. Achievements We have conducted a systematic review to extract all health-related quality of issues that are relevant for brain tumour patients. This resulted in an item list of items that was evaluated by 27 patients and 6 healthcare professionals in phase 1 of the project.
We recently finished patient recruitment for phase 1. We expect to start phase 3 in the beginning of October Although the questionnaire has proven to be successful in measuring HRQoL, the questionnaire was developed more than 20 years ago. Since then, treatments have changed and patients may now experience different symptoms. These symptoms are not captured by the current questionnaire, warranting an update. Related questionnaire.
EORTC Quality of Life Questionnaire - Brain Cancer Module (EORTC QLQ-BN20)
EORTC Quality of Life Questionnaire - Core Questionnaire (EORTC QLQ-C30)
EORTC QLQ-BN20 PDF